Lebrikizumab monotherapy was efficacious in improving atopic dermatitis in 80% of patients at 1 year, according to results from two phase 3 trials announced by Eli Lilly and Company.
The 52-week, randomized, double-blind, placebo-controlled, parallel-group phase 3 ADvocate 1 and 2 trials randomly assigned patients to receive 500 mg of lebrikizumab — an investigational interleukin-13 inhibitor — initially and at 2 weeks, followed by 250 mg or placebo every 2 weeks during a 16-week treatment period.
After week 16, those who achieved a clinical response, defined as EASI75, were again